🇺🇸 PTCT — PTC Therapeutics, Inc.

Salud Compra
← Volver

Precio actual

65,67 USD

Máx. histórico

89,55

119 días

Caída desde máximo

-26,67%

Rango 52 semanas

58,80 – 90,87

Variación hoy

-4,79%

Cierre anterior

68,97

Rango de hoy

65,45 – 69,59

Volumen hoy

1.228.468

Peor caída histórica

-94,60%

17/03/2015 → 03/11/2016

Recuperado en 3305 días

Volatilidad anualizada ⓘ

72,98%

Información
Nombre completo
PTC Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
991
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
100,47 USD (puede no estar actualizado)
Primera cotización
20/06/2013
Precio actualizado
hace 2 horas
Sobre la empresa

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
24/07/2014 28,61 29,10 27,55 27,90 -1,59% 5,42% 232.400
23/07/2014 27,22 28,45 27,21 28,35 +5,31% 4,56% 317.000
22/07/2014 25,51 27,17 25,04 26,92 +9,74% 8,35% 254.100
21/07/2014 23,55 24,90 22,86 24,53 +2,98% 8,66% 104.800
18/07/2014 23,16 23,89 22,70 23,82 +2,72% 5,14% 150.000
17/07/2014 23,05 24,52 22,90 23,19 -1,24% 7,03% 243.500
16/07/2014 24,45 24,45 23,16 23,48 -3,41% 5,30% 168.000
15/07/2014 24,50 24,62 23,21 24,31 -1,10% 5,76% 232.100
14/07/2014 24,97 24,97 24,14 24,58 +0,29% 3,32% 69.000
11/07/2014 24,34 25,93 24,16 24,51 +0,37% 7,27% 110.400
10/07/2014 24,02 25,25 23,58 24,42 -2,83% 6,95% 197.500
09/07/2014 25,10 25,99 24,43 25,13 +0,32% 6,22% 231.500
08/07/2014 26,68 26,70 24,57 25,05 -6,21% 7,98% 228.100
07/07/2014 27,99 27,99 26,02 26,71 -2,02% 7,04% 267.200
03/07/2014 27,35 27,74 26,80 27,26 +0,15% 3,44% 66.200
02/07/2014 27,73 28,31 26,92 27,22 -2,44% 5,01% 187.500
01/07/2014 26,29 28,50 26,28 27,90 +6,73% 8,44% 435.600
30/06/2014 27,70 28,48 25,80 26,14 -4,95% 9,68% 315.600
27/06/2014 26,54 27,98 26,47 27,50 +2,69% 5,69% 1.946.800
26/06/2014 26,88 26,99 26,27 26,78 +0,11% 2,70% 225.400
25/06/2014 25,97 26,99 25,60 26,75 +1,98% 5,35% 211.600
24/06/2014 26,55 26,98 25,78 26,23 -1,39% 4,52% 189.700
23/06/2014 26,90 26,92 25,65 26,60 -0,60% 4,72% 270.200
20/06/2014 26,25 26,98 25,61 26,76 +2,33% 5,22% 702.600
19/06/2014 26,20 26,45 25,28 26,15 -0,30% 4,47% 253.300
18/06/2014 25,37 26,35 24,91 26,23 +2,94% 5,68% 308.900
17/06/2014 25,40 25,81 24,94 25,48 +0,71% 3,43% 161.000
16/06/2014 25,33 25,65 24,65 25,30 +0,28% 3,95% 300.000
13/06/2014 25,57 25,57 24,06 25,23 -0,47% 5,91% 168.100
12/06/2014 25,55 25,82 24,88 25,35 -2,01% 3,68% 175.800